FY2025 · ended Dec 31, 2025 · Revenue $9.68M, -64.0% YoY · Filed Mar 25, 2026
Precigen, Inc. (PGEN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.7 million and a net loss of $250.6 million. Free cash flow was -$89.8 million. As of Sep 30, 2026 it held $51.0 million in cash and investments and $98.6 million in total debt.
Revenue
$9.68M
-64.0% vs prior year
Net income (TTM)
$24.41M
+109.9% vs year-ago TTM
Operating cash flow (TTM)
$-73.21M
-0.8% vs year-ago TTM
Free cash flow (TTM)
$-74.32M
+1.7% vs year-ago TTM
EPS (TTM)
$0.06
+107.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
353.93M
+19.9% vs prior year
Net cash
$-47.63M
as of Sep 30, 2026
Operating margin
-1141.1%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Germantown, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1356090
- Former names
- INTREXON CORP (until Jan 22, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.7M | — | — | $26.9M | $14.3M |
| Operating income | -$110.5M | — | — | — | — |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M | -$92.2M |
| Diluted EPS | -$1.37 | -$0.47 | -$0.39 | $0.14 | -$0.47 |
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M | -$55.8M |
| Free cash flow | -$89.8M | -$76.8M | -$68.5M | -$70.0M | -$63.0M |
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M |
| Stockholders' equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M |
| Cash and investments | $100.4M | $97.9M | $62.9M | $56.0M | $157.2M |
| Total debt | $98.3M | $5.5M | $7.1M | $51.4M | $191.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 24, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 1001 Precigen, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.